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ABSTRACT
Background: Peritoneal dissemination and retroperitoneal lymph node 
involvement are main routes for progression of epithelial ovarian cancer (EOC). 
Vascular endothelial growth factor (VEGF) mediated angiogenesis has been identified 
as an important mechanism promoting tumour progression.
Methods: Tumour tissue of 100 patients with EOC was analysed for protein 
expression of vascular endothelial growth factor (VEGF)-A, -C, -D by Western Blot 
analysis. Expression patterns in patients with ‘extensive intraperitoneal’ metastases 
(pT3c pN1 and pT3b-pT3c pN0, n=80) were compared to patients with ‘predominantly 
retroperitoneal’ metastases (pT1a-pT3b, pN1, n=20). Overall and progression-free 
survival was analysed by Kaplan-Meier method.
Results: While no significant differences in expression levels among the different 
modes of metastases were noted for VEGF-A and -D, VEGF-C expression was significantly 
higher in the group of predominantly retroperitoneal metastases compared to the group 
with extensive intraperitoneal metastases. Patients with high VEGF-C expression had 
a significantly worse overall survival compared to patients with low expression levels.
Conclusions: Retroperitoneal tumour progression in EOC patients is associated 
with high VEGF-C expression. VEGF-C may serve as a molecular marker to identify 
patients with assumed high risk for lymphatic metastases, who might benefit from 
specific treatment strategies.
INTRODUCTION
Epithelial ovarian cancer (EOC) represents the 
leading cause of death in gynaecological malignancies 
[1]. EOC progresses mainly through extensive 
intraperitoneal and/or retroperitoneal (lymphatic) tumour 
spread, while distant metastases are rarely seen [2]. So 
far, the biologic background of these two different modes 
of progression is poorly understood. Recent investigations 
have shown that the tumour cell differentiation status 
(epithelial-mesenchymal-transition) may influence the 
route of metastases in ovarian cancer [3]. Accordingly, 
we could previously show that strong expression of an 
85 kDa fragment of the epithelial marker E-Cadherin 
in ovarian cancer cells appears to be associated with 
intraperitoneal metastases [4]. Contrarily, other analyses 
revealed that mesenchymal tumour cells exhibited locally 
restricted tumour growth [3]. Highly metabolic tumour 
cells in locally growing tumour masses are dependent 
on vascular endothelial growth factor (VEGF) mediated 
angiogenesis [5]. The VEGF family consists of VEGF-
A,-C,-D and induces different cascades via their receptor-
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 26), pp: 43218-43227
Research Paper
Oncotarget43219www.impactjournals.com/oncotarget
Table 1: Patient characteristics according to the pattern of tumour dissemination
 Overall cohort Extensive intraperitoneal group
Predominant 
retroperitoneal group p-value
No. of patients 100 (100%) 80 (80.0%) 20 (20.0%)  
Age at diagnosis 
(years)    0.84b
 Median 62 62 62  
 Range 33-84 33-84 47-75  
Tumour stage    < 0.001a
 pT1c 3 (3%) 0 (0%) 3 (15%)  
 pT2b 1 (1%) 0 (0%) 1 (5%)  
 pT2c 2 (2%) 0 (0%) 2 (10%)  
 pT3a 2 (2%) 0 (0%) 2 (10%)  
 pT3b 13 (13%) 1 (1.25%) 12 (60%)  
 pT3c 79 (79%) 79 (98.75%) 0 (0%)  
Lymph node status    < 0.001a
 N0 40 (40%) 40 (50%) 0 (0%)  
 N1 60 (60%) 40 (50%) 20 (100%)  
Number of resected 
lymph nodes    0.043b
 Median 41 40 49  
 Range 1-97 1-94 1-97  
Mode of tumour 
dissemination    < 0.001a




40 (40%) 40 (50%) 0 (0%)  




20 (20%) 0 (0%) 20(100%)  
  Two-sided group 
(pT3c, pN1) 40 (40%) 40 (50%) 0 (0%)  
Grading    0.18c
 G1 4 (4%) 3 (3.75%) 1 (5%)  
 G2 24 (24%) 22 (27.5%) 2 (10%)  
 G3 72 (72%) 55 (68.75%) 17 (85%)  
Histologic subtype    0.09a
 Serous 85 (85%) 71 (88.75%) 14 (70%)  
 Endometrioid 4 (4%) 2 (2.5%) 2(10%)  
 Clear cell 3 (3%) 1 (1.25%) 2(10%)  
  Mixed 
differentiation 6 (6%) 5 (6.25%) 1 (5%)  
  Not determined/
unknown 2 (2%) 1 (1.25%) 1 (5%)  
(Continued )
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tyrosine-kinases VEGFR-1, VEGFR-2, VEGFR-3 to 
exhibit their various biological effects. In this context, 
VEGF-C and -D bind VEGFR-3 and promote additional 
lymphangiogenesis [6].
The aim of the present study was to identify the 
diagnostic potential of the VEGF family for identification 
of ovarian cancer patients being at high risk for 
retroperitoneal metastases. Identifying these patients may 
enable tailored therapeutic strategies to improve their 
prognosis and reduce morbidity.
RESULTS
Tumours with lymph node metastases exhibit 
high levels of VEGF-C expression
Tumour samples of all included 100 patients were 
analysed for VEGF-A, VEGF-C and VEGF-D expression 
by Western Blot, including 80 (80%) with ‘extensive 
intraperitoneal’ tumour growth and 20 patients (20%) with 
‘predominant retroperitoneal’ tumour involvement. Patient 
characteristics were balanced between both groups except 
for an expected higher rate of large bowel resections (69% 
vs 40% p=0.005) and lower number of resected lymph 
nodes (median 40 vs 49 lymph nodes p=0.043) in patients 
with ‘extensive intraperitoneal’ tumour growth (Table 1).
For VEGF-A no significant difference in 
expression levels between the different groups was found 
(‘predominant retroperitoneal’ vs. ‘extensive intraperitoneal’ 
metastases: median 1.18 vs 1.09, p=0.50, Figures 1, 2A).
A significantly higher expression of VEGF-C could 
be detected in the ‘predominant retroperitoneal’ group 
compared to the ‘extensive intraperitoneal’ group (median 
1.14 vs 0.42, p=0.001, Figures 1, 2B).
Expression of VEGF-C in tumours with solely 
intraperitoneal metastases within the ‘extensive 
intraperitoneal’ group significantly differed compared 
to tumours with retroperitoneal involvement. Median 
expression levels of these tumours were significantly 
lower compared to the ‘predominant retroperitoneal’ 
 Overall cohort Extensive intraperitoneal group
Predominant 
retroperitoneal group p-value
Surgical procedures     
  Large bowel 
resection 63 (63%) 55 (68.75%) 8 (40%) 0.002a
  Small bowel 
resection 8 (8%) 7 (9.6%) 1 (5%) 0.35a
  Upper abdomen 
interventions     
  Liver 29 (29%) 25 (31,25%) 4 (20%) 0.23a
  Spleen 19 (19%) 17 (21.25%) 2 (10%) 0.20a
  Pancreas 3 (3%) 2 (2.5%) 1 (5%) 0.50a
Postoperative 
residual tumour    0.58a
 Microscopic 78 (78%) 62 (77.1%) 16 (80%)  
 Macroscopic 21 (21%) 17 (21.6%) 4 (20%)  
Preoperative CA 125 
level (kU/l)    0.32b
 Median 386 401 307  
 Range 14-13089 14-13089 34-2802  
Postoperative CA 125 
level (kU/l)    0.79b
Median 103 101 121  
Range 11-1267 11-1267 28-896  
Overview of the clinical characteristics of all included patients with EOC (n = 100). A total of 20 patients with predominant 
retroperitoneal tumour dissemination are opposed to 80 patients with extensive intraperitoneal tumour involvement. Both 
groups were tested with Pearson-Chi-Quadrat test (a), ANOVA analysis (b), as well as with the Kruskal Wallis (c) test upon 
differences. Statistically significant P values are printed in bold.
FIGO: International Federation of Gynecology and Obstetrics; kU/l: kilo Units per liter.
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group (median 0.60 vs 1.14, p=0.03, Figure 2B) and 
higher compared to tumours with both types of metastases 
(median 0.60 vs 0.35, p=0.007, Figure 2B).
In accordance with VEGF-C, a semi-quantitative 
analysis on VEGF-D expression reveals similar trends 
among the different groups of metastases, although without 
statistical significance (‘predominant retroperitoneal’ vs 
extensive ‘intraperitoneal metastases’: mean 1.33 vs 0.96, 
p=0.09, Figures 1, 2C).
VEGF-C correlates with postoperative 
residual tumour
No significant correlations between VEGF-C and 
VEGF-A,-D expression as well as clinical characteristics 
like prae-/post CA125 values, age and grading were noted. 
However, VEGF-C exhibits a significant correlation 
to postoperative residual tumour (Pearson: r=0.225, 
p= 0.025, Table 2).
In addition, decreasing VEGF-D values were noted 
with rising age of patients (Pearson: r= -0.205, p=0.045, 
Table 2), while VEGF-A is correlated with post-CA125 
values (Pearson: r= 0.242, p=0.033, Table 2).
Patients with high VEGF-C expression had a 
significantly worse overall survival
In survival analyses, no prognostic differences 
with regard to modes of progression were noted in terms 
of progression-free survival (PFS, log Rank p=0.80, 
Supplementary Figure 1A. and overall survival (OS), log 
Rank p=0.79, Supplementary Figure 1B).
Subsequently, the overall patient cohort was 
divided into two groups according to the median VEGF-C 
expression values detected by Western Blot analysis. 
The group of patients with low VEGF-C expression 
(n=50) consisted of 5 patients with ‘predominant 
retroperitoneal’ (10%), 17 patients with ‘solely 
intraperitoneal’ (34%) and 28 patients with ‘both types’ 
of metastases (56%). In contrast, the group with high 
VEGF-C expression is composed of 15 patients with 
‘predominant retroperitoneal’ (30%), 23 patients with 
‘solely intraperitoneal’ (46%) and 12 patients with ‘both 
types’ of metastases (24%, Supplementary Figure 2).
Regarding PFS there was no statistically significant 
association with high VEGF-C expression compared to 
low expression (median 23 vs 23 months; HR1.44, 95%-
CI 0.89-2.31, p=0.13; Log Rank p=0.13, Figure 3A). 
Figure 1: Expression of VEGF-A, VEGF-C, VEGF-D according to the mode of tumour progression. Representative 
expression of VEGF-A, VEGF-C, VEGF-D in the different types of tumour dissemination. Protein lysates from the breast cancer cell line 
MCF7 were used as positive controls for VEGF-A, –C and –D. Equal amounts of protein lysate (20 μg) were loaded per well.
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Figure 2: Quantitative expression of VEGF-A, VEGF-C, VEGF-D according to the mode of tumour progression. (A) 
For VEGF-A no significant differences in expression levels between the different groups could be detected. (B) VEGF-C with significantly 
higher expression in patients with ‘predominant retroperitoneal‘ metastases compared to ‘extensive intraperitoneal’ metastases (median 
1.14 vs 0.42, p=0.001) and compared to patients with both types of metastases (median 1.14 vs 0.35, p=0.00002), as well as compared to 
patients with solely intraperitoneal metastases (median 1.14 vs 0.60, p=0.03). VEGF-C expression is significantly higher in the group of 
solely intraperitoneal metastases compared to both types of metastases (median 0.60 vs 0.35, p=0.007) (C) VEGF-D exhibits a trend of 
higher expression levels in patients with ’predominant retroperitoneal’ metastases compared to the ’extensive intraperitoneal’ group (mean 
1.33 vs 0.96, p=0.09), although without statistical significance.
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However, patients with high VEGF-C expression values 
had a significantly impaired OS with 41 versus 56 months 
(HR 2.02, 95%-CI 1.12-3.63, p=0.019; Log Rank p=0.016, 
Figure 3B).
DISCUSSION
Following the results of the present explorative 
study including tumour samples from 100 patients with 
epithelial ovarian cancer, we could identify VEGF-C 
as a potential molecular marker attributing the risk for 
retroperitoneal tumour progression to ovarian cancer 
patients.
VEGF-C is significantly higher expressed in the 
group of patients with ‘predominant retroperitoneal’ 
metastases compared to the group of ‘extensive 
intraperitoneal’ tumour involvement. Although the 
different modes of tumour progression were not directly 
correlated with differences in survival, a significantly 
Table 2: Correlation of VEGF-A,-C,-D expression and clinical/pathological patient characteristics
 VEGF-C expression VEGF-D expression VEGF-A expression
VEGF-A expression r = 0.062; p=0.538 r = -0.004; p=0.969  
VEGF-D expression r = 0.026 ; p=0.802   
Pre-CA125 value r = 0.024; p=0.821 r = 0.022 ; p=0.839 r = 0.154; p=0.150
Post-CA125 value r = 0.056; p=0.623 r = 0.134; p=0.256 r = 0.242; p=0.033
Age r = - 0.058 ; p=0.569 r = -0.205; p=0.045 r = 0.123; p=0.223
Grading r = 0.018 ; p=0.861 r = - 0.045; p=0.663 r = 0.061; p=0.544
Postoperative residual 
tumour r = 0.225; p=0.025 r = 0.033; p=0.753 r = 0.0001; p=0.999
Postoperative residual tumour was categorized in ‘postoperative no tumour residual’, ‘microscopic tumour residual’, 
‘tumour residual <1cm’ and ‘tumour residual > 1 cm’. p = p-value; correlation coefficient: r = Pearson. Bold values indicate 
statistically significant correlations.
Figure 3: Progression-free and overall survival according to the expression level of VEGF-C. By dividing the overall 
patient cohort into two groups according to the median VEGF-C expression by Western Blot, two groups with low (n=50) and high (n=50) 
VEGF-C expression were generated. (A) Progression-free survival shows no prognostic differences in relation to VEGF-C expression 
(median 23 vs 23 months; HR1.44, 95%-CI 0.89-2.31, p=0.13; Log Rank p=0.13). (B) Patients with high VEGF-C expression have a 
significantly shorter overall survival compared to patients with low VEGF-C expression levels with a median of 41 versus 56 months (HR 
2.02, 95%-CI 1.12-3.63, p=0.019; Log Rank p=0.016).
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shorter overall survival for patients with high VEGF-C 
expression was noted, which supports a possible 
prognostic impact of VEGF-C mediated retroperitoneal 
metastases. Nevertheless, as we know that patients with 
extensive intraperitoneal tumor dissemination usually 
have an impaired prognosis, it underlines that prognostic 
differences are not regulated by one single factor and that 
multiple other factors influence the prognosis of patients. 
Accordingly but not-significant, VEGF-D shows similar 
trends among the different groups of metastases, while 
expression levels for VEGF-A did not differ in our cohort.
As previously described, the VEGF-C/VEGFR-3 
pathway acts as an enhancer of ovarian cancer progression 
through autocrine and paracrine mechanisms, hence 
offering a potential target for therapeutic interventions 
[9]. Higher intratumour VEGF-C expression and worse 
clinical outcome of ovarian cancer patients is associated 
with the presence of lymphatic space invasion which 
may act as an indicator of lymph node metastases [10]. 
According to this observation, we could demonstrate that 
VEGF-C expression in tumours with solely intraperitoneal 
metastases significantly differed compared to tumours 
with retroperitoneal involvement.
In line with previous investigations [3], 
we hypothesise that tumours with predominant 
retroperitoneal metastases seem to have a more 
mesenchymal tumour cell biology with high VEGF-C 
levels and low E-Cadherin expression in contrast 
to tumours with ‘extensive intraperitoneal’ tumour 
distribution [4] (Figure 4). Gene signatures in high–grade 
serous ovarian cancer have been identified with high 
VEGF-C mRNA levels in the ‘mesenchymal’ molecular 
subtype, which shows significantly shorter survival 
rates compared to ‘immunoreactive’, ‘differentiated’ 
or ‘proliferative’ subtypes [11]. In contrast, tumours in 
the subgroup with ‘solely intraperitoneal’ metastases 
are characterised by an epithelial phenotype with 
high E-Cadherin [4] as well as low VEGF-C and –D 
expression, which might promote intraperitoneal 
tumour dissemination (Figure 4). VEGF-C expression 
levels in tumours exhibiting intraperitoneal as well 
as retroperitoneal tumour involvement were lower 
compared to patients with solely intraperitoneal 
metastases which may indicate a dedifferentiation of 
tumour cells in tumours with both modes of progression 
compared to tumours with solely intraperitoneal or 
only predominant retroperitoneal metastases. As 
tumours in more advanced tumour stage with both 
types of metastases are characterised by a significantly 
lower VEGF-C expression compared to patients with 
predominant retroperitoneal metastases, this may 
indicate a potential of VEGF-C to estimate the risk for 
early retroperitoneal metastases. Reliable identification 
of patients in early stage at high risk for retroperitoneal 
Figure 4: Expression patterns determining different types of metastases in EOC. Tumour cells of patients with ‘predominant 
retroperitoneal‘ metastases are characterised by a mesenchymal tumour type with low E-Cadherin and high VEGF-C and –D expression, 
which probably leads to local intrapelvic tumour growth and lymphatic metastases instead of disseminating diffusely intraabdominal. The 
tumour type of patients with solely intraperitoneal metastases is otherwise characterised by an epithelial phenotype with high E-Cadherin 
and low VEGF-C and -D expression, which potentially leads to ‘extensive intraperitoneal’ tumour dissemination (A: ascites, LV: lymph-
vessel, TC: tumour cell).
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tumour progression would be highly interesting to tailor 
therapeutic strategies regarding surgery and systemic 
therapy.
Monoclonal antiangiogenic therapy with 
bevacizumab, an antibody that targets VEGF-A, 
has been incorporated into guidelines for firstline 
therapy of EOC in Europe with a proven effect on 
progression-free survival in FIGO stages IIIB, IIIC 
und IV (FIGO classification before 2014, UICC 7th 
edition) [12]. Prognostic markers and strategies for 
patient selection regarding antiangiogenic therapy have 
not been established so far. Therefore, it would be of 
special interest to be able to identify patients in early 
tumour stages, who might also benefit from additional 
anti-angiogenic therapy. In contrast to bevacizumab, 
multikinase inhibitors address several intracellular 
tyrosine kinases and initiate additional therapeutic 
effects within the antiangiogenic treatment concept 
[13]. In this context, cediranib serves as an example by 
targeting VEGFR-3 in addition to VEGFR-1, and -2. As 
VEGF-C and –D exert their biological effects mainly 
via the VEGFR-3-pathway in addition to VEGF-A, 
multikinase inhibitors may have the potential to be 
used as specific antiangiogenic drug for tumours with 
high VEGF-C- levels at high risk for retroperitoneal 
metastases. Furthermore, as a future perspective its 
expression might be used to characterise patients in 
early cancers who do not require radical systematic 
lymphadenectomy in staging laparotomies due to their 
low biological probability of lymph node metastases.
The identification of molecular markers for 
individual therapy is urgently required to tailor therapy 
of patients with EOC more individually. Even though 
an intraoperative decision for lymphadenectomy 
depending on molecular VEGF-expression is not yet 
possible, VEGF-C could represent a molecular marker to 
identify patients with high risk of lymphatic metastases 
who benefit from retroperitoneal surgery and specific 
antiangiogenic therapy (e.g. following diagnostic 
laparoscopy). However, further experimental and clinical 
investigations will be necessary to verify the benefit of 
an antiangiogenic therapy in form of individual VEGF-C 
and -D pathway inhibitors.
MATERIALS AND METHODS
Patients
A total of 100 patients with EOC treated at the 
University Medical Centre Hamburg-Eppendorf between 
1995 and 2012 were included in the study. All patients 
underwent primary debulking surgery according to 
current German guidelines [7]. Patient cohorts were 
classified according their mode of tumour progression 
with two different types of metastatic spread. While 
a total of 20 patients had predominant retroperitoneal 
tumour involvement (‘predominant retroperitoneal’, 
pT1a-pT3b, N1), the other 80 patients exhibited extensive 
intraperitoneal metastases in tumour stage pT3b-
pT3c, pN0 and pT3c pN1 (‘extensive intraperitoneal’). 
This cohort was further subdivided into a subgroup 
of 40 patients with extensive intraperitoneal tumour 
dissemination without lymph node involvement (pT3b-
pT3c pN0, solely intraperitoneal metastases) and a 
subgroup of 40 patients with extensive intraperitoneal 
and retroperitoneal metastases (pT3c, N1, both types of 
metastases).
Detailed patient characteristics are presented in 
Table 1. All patients gave written informed consent 
to access their tissue and review their clinical records 
according to our investigational review board and ethics 
committee guidelines (#200814). Clinical data was 
retrieved from a detailed database providing information 
on clinicopathologic factors, histologic classifications and 
therapeutic procedures. Clinical outcome of all patients 
was followed from date of first diagnosis until the end 
of 2014.
Tissue samples
As described previously [4] tissue samples were 
obtained intraoperatively and immediately stored in 
liquid nitrogen as fresh frozen samples. The histological 
characteristics of each sample were evaluated on cryo-cut 
and haematoxylin-eosin-stained sections. The tissue was 
tailored if necessary to obtain at least 70% tumour cells in 
the sample used for protein extraction.
Protein extractions
As described previously [4] samples of approximately 
100 mg were cut from the tissue and pulverised using 
a micro-dismembrator (Braun-Melsungen, Melsungen, 
Germany) for 2 minutes and 45 seconds at 200 r.p.m. 
Proteins were lysed in ice-cold sample buffer (50mM Tris 
pH 6.8, 1% sodium dodecyl sulphate (SDS), 10% sucrose 
and 10 μl/ml protease inhibitor cocktail (Sigma, Taufkirchen, 
Germany)). The protein concentration was determined 
following standard protocols and using bovine serum 
albumin protein standards.
Western blot analysis
For Western blot analysis equal amounts of protein 
lysate (20 μg) were analysed per well. The proteins were 
separated on a 10 percent polyacrylamide gel (11% 
Glycerin, aqua dest., 10% SDS, Tris and 10% Acrylamid) 
and transferred to polyvinylidene difluoride membranes 
(Merck Millipore KGaA Darmstadt, Germany). After that, 
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the membranes were blocked with 5% nonfat dry milk 
(Bio-Rad Laboratories, USA) in TBST (TBS: 50mM Tris, 
150mM NaCl, pH 7.4 with 10% TWEEN 20), washed 
in TBST and incubated with the primary antibody. The 
monoclonal antibody for VEGF-A (Abcam ab46154), 
1:8000, Cambridge United Kingdom) was diluted in 
5% nonfat dry milk in TBST, whereas the monoclonal 
antibodies for VEGF-C (sc374628, 1:200, Santa Cruz 
Biotechnology, Heidelberg, Germany) and VEGF-D 
(H144 sc13085, 1:1000, santa cruz) were diluted in 5% 
BSA in TBST. All primary antibodies were incubated at 
4°C overnight. After incubation, membranes were washed 
in TBST and incubated with the corresponding secondary 
antibody (anti rabbit sc 2054, for VEGF-A and –D; anti 
mouse sc 2005 for VEGF-C, all purchased from santa 
cruz) in 1.5% nonfat dry milk in TBST for one hour at 
room temperature. Finally, after washing in TBST, the 
detection was carried out with the SuperSignal West Pico 
chemoluminescent kit (Thermo Scientific, Rockford, 
USA) to visualise the protein expression on FUJI-super 
RX medical x-ray films (Tokyo, Japan).
Band intensities were quantified by densitometry 
(GS-700 Imaging Densitometer, BioRad, Munich, 
Germany). Protein lysates from the breast cancer cell line 
MCF7 were used as positive controls for VEGF-A, –C and 
-D. All detected bands of the investigated proteins except 
for VEGF-D were standardised with the positive controls, 
which were defined as 100 percent. Expression values 
were normalised to GAPDH (Santa Cruz FL 335; 1:5000), 
as loading control. VEGF-D was analysed in a semi-
quantitative way because of unmanageable background 
signals. For VEGF-C, bands at 60 kDa were detected in 
our collective. As previously reported we assessed the 60 
kDa band as heterodimer of the active VEGF-C monomers 
of 29 kDa and 31 kDa [8].
Statistical analysis
Values representing VEGF-A, VEGF-C and 
VEGF-D expression levels were logarithmised and tested 
among the different cohorts by ANOVA analysis, as well 
as post hoc with the Least Significant Difference Test 
(LSD). VEGF-C expression was correlated by Pearson 
with the VEGF-A and -D as well as with clinical- and 
pathological parameters. P-values <0.05 were considered 
to be statistically significant. Boxplots were diagrammed 
on the basis of absolute VEGF expression levels. 
Univariate survival analyses were made by Kaplan Meier 
method and cox regression and are not independent 
findings. All statistical analyses were carried out with 
SPSS (IBM SPSS Statistics version 22 for windows).
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